Biopharmaceutical company Soligenix Inc (Nasdaq:SNGX) revealed on Thursday that it expects to receive the patent from the US Patent Office titled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity" on 9 April 2019.
This new patent, which has been assigned the number #10,253,068, claims composition of matter for novel innate defence regulator (IDR) analogs, expanding patent protection to diverse analog structures. Therapeutic use claims in oral mucositis, colitis and infectious disease, both alone and in conjunction with antibiotics, will also issue.
According to the company, Dusquetide (the active ingredient in SGX942) is a novel, first-in-class IDR. It modulates the response of the innate immune system in response to various stimuli, including infection, tissue damage and inflammation. IDRs have no direct antibiotic activity but, by modulating the host's innate immune system responses, increase survival after infections caused by a broad range of bacterial Gram-negative and Gram-positive pathogens.
SGX942 demonstrated positive results in a Phase 2 study in the treatment of oral mucositis in head and neck cancer (HNC) patients. In addition to the oral mucositis findings, an increased incidence of "complete response" of tumour at the one-month and 12-month follow-up visits were observed. Decreases in infection rate and an increase in the 12-month survival rate were observed, stated the company.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial